Open AccessMolecular testing for acute myeloid leukemia
Author(s) -
Dahui Qin
Publication year - 2021
Publication title -
cancer biology and medicine
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2095-3941
DOI - 10.20892/j.issn.2095-3941.2020.0734
Subject(s) - myeloid leukemia , sanger sequencing , pyrosequencing , risk stratification , medicine , molecular diagnostics , polymerase chain reaction , disease , leukemia , oncology , computational biology , gene , bioinformatics , dna sequencing , biology , genetics
In the era of personalized medicine, information on molecular change at the gene level is important for patient care. Such information has been used for disease classification, diagnosis, prognosis, risk stratification, and treatment, which is especially important in cancer patient care. Many molecular tests exist and can be used to detect the molecular changes at gene level. These tests include, but are not limited to, karyotyping, endpoint polymerase chain reaction (PCR), real-time PCR, Sanger sequencing, pyrosequencing, next-generation sequencing, and so forth. How to use the right tests for the right patients at the right time is essential for optimal patient outcome. This review puts together some information on molecular testing for acute myeloid leukemia.